From wiki-pain
Revision as of 03:11, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0
Pain Relevance 0.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2D6, CYP1A2) oxidoreductase activity (CYP2D6, CYP1A2) endoplasmic reticulum (CYP2D6, CYP1A2)
mitochondrion (CYP2D6) enzyme binding (CYP1A2)
CYP2D6 (Homo sapiens)
CYP1A2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 33 100.00 Very High Very High Very High
Nicotine 3 68.80 Quite High
opioid receptor 1 68.56 Quite High
Serotonin 36 66.12 Quite High
Potency 3 63.08 Quite High
noradrenaline 25 61.08 Quite High
depression 41 48.60 Quite Low
Pain 2 23.04 Low Low
sSRI 41 12.88 Low Low
fluoxetine 23 12.56 Low Low
Disease Link Frequency Relevance Heat
Depression 48 48.60 Quite Low
Liver Disease 1 39.44 Quite Low
Reprotox - General 1 1 34.96 Quite Low
Reprotox - General 2 6 34.08 Quite Low
Vomiting 8 30.28 Quite Low
Major Depressive Disorder 27 18.80 Low Low
Overdose 2 10.60 Low Low
Syndrome 2 6.00 Low Low
Stress 9 5.00 Very Low Very Low Very Low
Xerostomia 7 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Extensive metabolism, predominantly via CYP1A2, to a lesser extent via CYP2D6, and at a very low rate via CYP2C9,151,152 has been reported, but the metabolites have no significant activity.153 Duloxetine is a moderate CYP2D6 inhibitor and may inhibit its own metabolism154,155 as well as the metabolism of CYP2D6 substrates, such as desimipramine.90,195 The inhibition or induction of CYP1A2 is not clinically important, and coadministration of duloxetine with CYP1A2 substrates does not necessitate their dose adjustment.193 However, potent inhibitors of CYP2D6 and CYP1A2 may result in enhanced duloxetine concentrations and a need for dose adjustment.191,193
Negative_regulation (inhibitors) of CYP2D6 Positive_regulation (result) of Localization (duloxetine) of CYP1A2 associated with duloxetine
1) Confidence 0.46 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0 Pain Relevance 0.62

General Comments

This test has worked.

Personal tools